Navigation Links
Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
Date:7/14/2008

the U.S. (UL 60601-1), Canadian (CSA C22.2 No. 601.1-M90), and European Union (EN60601-1) medical electrical safety standards. In addition, the RapidBlue console passed the stringent UL 471 Standard for commercial refrigerators and freezers.

InnerCool's RapidBlue(TM) and CoolBlue(TM) Temperature Modulation Systems

InnerCool's RapidBlue system for high-performance endovascular temperature modulation includes a programmable console with an enhanced user-friendly interface and touch-panel screen and powers the low-profile, flexible Accutrol(R) catheter to quickly modulate patient temperature at cooling rates of 4-5 degrees Celsius per hour. The Accutrol catheter, which has a flexible metallic temperature control element(TM) (TCE) and a built-in temperature feedback sensor to provide fast and precise patient temperature control, can accurately measure core body temperature within 0.1 degree Celsius of pulmonary artery temperature. Its novel software control algorithm provides automated and precise body temperature control, eliminating the use of peripheral temperature probes which are generally slow in responding to core temperature changes.

The RapidBlue console and Accutrol catheter can quickly and accurately modulate whole body temperature without introducing or exchanging any fluid within the body. The system functions by programmably circulating cold or warm saline in a closed circuit within the catheter to either cool or warm its outer metallic surface, which effectively conducts heat out of or into the surrounding bloodstream. The unique design of InnerCool's TCE(TM), which is both thermally conductive and includes alternating surface helices to promote mixing around the TCE, further enhances heat transfer and enables rapid patient temperature modulation, even in obese patients. The catheter and TCE have a covalently-bonded heparin coating for hemo-compatibility and the catheter can be readily placed in an operating room or intensive care se
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardium Announces Follow-On Direct Investment by Institutional Investor
2. Cardium Selected for Inclusion in Russell Microcap Index
3. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardium Launches New AWARE Clinical Study Website
5. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
6. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
11. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... CORDOVA, Calif., Nov. 5 ...upplier of innovative products for processing and ...or the first quarter of fiscal 2010. ,, For the...orted revenues of $5.2 million, a 15 percent incre...rter a year ago. The Company said the key contribu...
(Date:11/5/2009)...OK, N.Y., Nov. 5 BioSpec...armaceutical company developing first-in-class col...cial results for the third quarter ended September...n September of this year, the FDA,s Arthritis Advi...of 12-0, the approval of XIAFLEX(TM) for the treat...
(Date:11/5/2009)...EGO, CA, November 5, 2009 /PRNewswire-FirstCall/ -...d on using proprietary taste receptor-based techno...e food, beverage, and ingredient supply industries...inancial results for the third quarter ended Septe... third quarter of 2009, compared to $4.0 million f...
(Date:11/5/2009)...YMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-First... ("BMP Sunstone" or the "Company") today announced...009 financial results on,Monday, November 9, 2009,...ill hold a conference call at 5:00 pm ET on Novemb... Listeners may access the call by,dialing 1-888-71...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BMP Sunstone to Report Third Quarter 2009 Financial Results 2
...Oct. 10 AstraZeneca (NYSE:,AZN) today announced t...s,approved once-daily SEROQUEL XR(R) (quetiapine f...eatment of the depressive episodes associated with...sociated with bipolar I,disorder, and the maintena...therapy to lithium or divalproex. SEROQUEL XR is t...
... 10 Takeda Pharmaceutical Company,Limited ("Taked...d,Development Center, Inc., a wholly owned United ...t the U.S. Food and Drug Administration (FDA) will...tin New Drug Application,(NDA) by the Prescription...., "In our most recent discussion with the FDA, i...
...No. 2 in ranking; up six spots from last year, ST...arning recognition as a leader in biotechnology no...or being a great place to work., Monsanto, headqu...in,the 2008 Top Biotech and Pharma Employers list ...mpany moved up six spots from number eight the,pri...
Other Biology Technology:FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 2FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 3FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 4FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 5FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 6FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 7FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 8FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 9FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Monsanto Recognized as Top Biotechnology Employer by Science Magazine 2
(Date:11/6/2009)...lebrate the 150th anniversary this month of the pu...n Institute of Biological Sciences (AIBS) is publi... Charles Darwin and his historic insights into evo... the University of California, Berkeley, and James... article, "Ten Myths About Charles Darwin," appear...
(Date:11/6/2009)...ETROIT, Nov. 6 Auburn Hills, MI-ba...) will be installing its locker system and patent-... at the U.S. Department of Health and Human Servic...ethesda, MD. The locker system will support the N...rotecting our nation,s medical research agency. T...
(Date:11/5/2009)...ational Association of Biology Teachers (NABT) wil...logical sciences at Naugatuck Valley Community Col...09 Evolution Education Award during the NABT annua...1-14 November 2009 in Denver, Colorado. , The Ev...ican Institute of Biological Sciences,(AIBS) and ...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2HPV Tied to Rare Head and Neck Cancer 59233 1HPV Tied to Rare Head and Neck Cancer 59233 2Authoritative Report on Home Health Care Experiences Released By Press Ganey 59229 1Authoritative Report on Home Health Care Experiences Released By Press Ganey 59229 2Authoritative Report on Home Health Care Experiences Released By Press Ganey 59229 3DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 1DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 2DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 3
...he Attendees, Choice Awards, NEW YORK, Dec. 5 Th...xposition (NECE) at Caesars Palace, Las Vegas, Nov...nomics decision makers and,ergonomics product sell...resenting all of the 50 states and a dozen foreign...GE, GM, Johnson & Johnson, Kaiser,Permanente, Lock...
...he University of Bonn and the University of Pittsb...o cardiac tissue of mice that had suffered heart a...thmias, thereby avoiding one of the most dangerous...covery, reported in this week,s issue of Nature, h... therapies to restore damaged heart tissue., The r...
...onal Academies have studied the health effects of ...omic bombs dropped on Hiroshima and Nagasaki, Japa...sion (ABCC), the study group was reorganized in 19...on (RERF), which is now a cooperative Japan-U.S. r...tributions of former and current ABCC/RERF employe...
Other Biology News:Record Attendance at the 2007 National Ergonomics Conference and Exposition 2Implanting embryonic cardiac cells prevents arrhythmias 2Atomic bomb survivor, scientists mark 60 years of long-term radiation study 2
NanoDrop ND-1000 UV-Vis Spectrophotometer from NanoDrop Technologies
Propidium Iodide from Calbiochem
Mouse Anti-Human PUM2 Monoclonal Antibody, Unconjugated, Clone 1C8 from Abnova Corporation
...; Deletion Cosmid Cloning Kit enables you to prepa...mary cosmid library of genomic DNA for subsequent ...fficiency cosmid library construction is accomplis...ls. First, genomic DNA is randomly sheared by pass...
Biology Products: